1512MO Perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo for locally advanced resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The first interim analysis of a randomized, phase III trial (DRAGON IV)

作者：Changhui Li, Yingjie Zheng, Zhen Shi, Li-Kuei Yang, Bo Zhang, Zhiqiang Wang, Huijiao Chen, Xiaohua Wang, Peng Zhao, Jiahong Dong, Chao Lian, Qingjun Zhao, Zheng Zheng, Andrew J. Zhang, Shan Xu, K. Wang, Fei Yuan, Yuan Tian, Kai Yin, Zheng Gang Zhu · 发表于：Annals of Oncology · 年份：2023 · DOI：10.1016/j.annonc.2023.09.1425 · 被引用次数：22 · 研究领域：Gastric Cancer Management and Outcomes、Gastrointestinal Tumor Research and Treatment、Colorectal Cancer Treatments and Studies